NeuroMetrix said on 20 May the Food and Drug Administration granted it de novo authorization to market its Quell neuromodulation device as an aid for reducing symptoms of fibromyalgia in adults with high pain sensitivity.
The Woburn, MA company received FDA breakthrough designation for use of Quell to treat fibromyalgia last July. The de novo...






